Tags

Type your tag names separated by a space and hit enter

High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure.
Clin Respir J. 2018 Jun; 12(6):2046-2056.CR

Abstract

INTRODUCTION

Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality.

OBJECTIVES

We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV).

METHODS

The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality.

RESULTS

Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P = .857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P = .845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P = .295), PaO₂ (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P = .899) and PaCO₂ (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P = .160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P = .743), PaO₂ (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P = .934) and PaCO₂ (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P = .422) after 24 hours were not significantly different.

CONCLUSION

There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Institute of Lifestyle Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea.

MeSH

AgedAged, 80 and overCannulaFemaleHumansHypercapniaIntensive Care UnitsMaleNasal CavityNoninvasive VentilationOxygenOxygen Inhalation TherapyPrognosisProspective StudiesRepublic of KoreaRespiratory InsufficiencySurvival Rate

Pub Type(s)

Journal Article

Observational Study

Language

eng

PubMed ID

29392846

Citation

Lee, Myoung Kyu, et al. "High Flow Nasal Cannulae Oxygen Therapy in Acute-moderate Hypercapnic Respiratory Failure." The Clinical Respiratory Journal, vol. 12, no. 6, 2018, pp. 2046-2056.

Lee MK, Choi J, Park B, et al. High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. Clin Respir J. 2018;12(6):2046-2056.

Lee, M. K., Choi, J., Park, B., Kim, B., Lee, S. J., Kim, S. H., Yong, S. J., Choi, E. H., & Lee, W. Y. (2018). High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. The Clinical Respiratory Journal, 12(6), 2046-2056. https://doi.org/10.1111/crj.12772

Lee MK, et al. High Flow Nasal Cannulae Oxygen Therapy in Acute-moderate Hypercapnic Respiratory Failure. Clin Respir J. 2018;12(6):2046-2056. PubMed PMID: 29392846.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. AU - Lee,Myoung Kyu, AU - Choi,Jaehwa, AU - Park,Bonil, AU - Kim,Bumjoon, AU - Lee,Seok Jeong, AU - Kim,Sang-Ha, AU - Yong,Suk Joong, AU - Choi,Eun Hee, AU - Lee,Won-Yeon, Y1 - 2018/03/05/ PY - 2016/11/20/received PY - 2017/8/28/revised PY - 2018/1/26/accepted PY - 2018/2/3/pubmed PY - 2018/11/27/medline PY - 2018/2/3/entrez KW - chronic obstructive pulmonary disease KW - exacerbation KW - intubation KW - mortality KW - pneumonia KW - respiratory failure SP - 2046 EP - 2056 JF - The clinical respiratory journal JO - Clin Respir J VL - 12 IS - 6 N2 - INTRODUCTION: Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality. OBJECTIVES: We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV). METHODS: The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality. RESULTS: Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P = .857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P = .845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P = .295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P = .899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P = .160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P = .743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P = .934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P = .422) after 24 hours were not significantly different. CONCLUSION: There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups. SN - 1752-699X UR - https://www.unboundmedicine.com/medline/citation/29392846/full_citation DB - PRIME DP - Unbound Medicine ER -